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Background: Dendritic cells (DC) are important antigen presentation cells that monitor, process, and present
antigen to T cells. Viruses that infect DC can have a devastating impact on the immune system. In this study, the
ability of bovine viral diarrhea virus (BVDV) to replicate and produce infectious virus in monocyte-derived dendritic
cells (Mo-DC) and monocytes was studied. The study also examined the effect of BVDV infection on Mo-DC
expression of cell surface markers, including MHCI, MHCII, and CD86, which are critical for DC function in immune
response.
Methods: Peripheral blood mononuclear cells (PBMCs) were isolated from bovine blood through gradient
centrifugation. The adherent monocytes were isolated from PBMCs and differentiated into Mo-DC using bovine
recombinant interleukin-4 (IL-4) and granulocyte-macrophage colony-stimulating factor (GMCSF). To determine the
effect of BVDV on Mo-DC, four strains of BVDV were used including the severe acute non-cytopathic (ncp)
BVDV2a-1373; moderate acute ncp BVDV2a 28508-5; and a homologous virus pair [i.e., cytopathic (cp) BVDV1b
TGAC and ncp BVDV1b TGAN]. The Cooper strain of bovine herpesvirus 1 (BHV1) was used as the control virus. Mo-DC
were infected with one of the BVDV strains or BHV-1 and were subsequently examined for virus replication, virus
production, and the effect on MHCI, MHCII, and CD86 expression.
Results: The ability of monocytes to produce infectious virus reduced as monocytes differentiated to Mo-DC, and was
completely lost at 120 hours of maturation. Interestingly, viral RNA increased throughout the course of infection in
Mo-DC, and the viral non-structural (NS5A) and envelope (E2) proteins were expressed. The ncp strains of BVDV
down-regulated while cp strain up-regulated the expression of the MHCI, MHCII, and CD86 on Mo-DC.
Conclusions: The study revealed that the ability of Mo-DC to produce infectious virus was reduced with its differentiation
from monocytes to Mo-DC. The inability to produce infectious virus may be due to a hindrance of virus packaging or
release mechanisms. Additionally, the study demonstrated that ncp BVDV down-regulated and cp BVDV up-regulated
the expression of Mo-DC cell surface markers MHCI, MHCII, and CD86, which are important in the mounting of immune
responses.
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Bovine viral diarrhea virus (BVDV) is an important dis-
ease of the cattle industry in the USA and worldwide.
The virus belongs to the family Flaviviridae and is a
single-stranded, positive-sense RNA virus with a genome
of approximately 12.5 kb [1]. BVDV can further be clas-
sified on the basis of genotype and biotypes. Specifically,
genotypes are divided into Type 1 (BVDV1) or Type 2
(BVDV2), and are distinguishable using monoclonal
antibodies [2], while BVDV biotypes are classified as ei-
ther cytopathic (cp) or non-cytopathic (ncp), based on
the effect the virus has on cell culture [3]. Likewise,
BVDV infection in cattle has multiple variations. Infec-
tion of the bovine fetus with ncp BVDV during the first
trimester often results in persistently infected (PI) calves
that are immunotolerant to BVDV, and thus remain a
source of infection to other animals. Additionally, super-
infection of PI animals with an antigenically homologous
cp strain of BVDV typically results in fatal mucosal dis-
ease [4]. In the acutely infected animal, initial infection
and replication of BVDV occurs in the oronasal mucosa
and oropharyngeal lymphoid tissue [5], and the subse-
quent systemic spread occurs through lymphatic and
blood circulation systems [6]. The BVDV virus can be
detected in the blood approximately 4 to 8 days after ini-
tial exposure, and the buffy coat sample comprises the
white blood cells (WBCs) present in peripheral blood,
typically contain more virus than serum [7]. The buffy
coat contains various antigen presenting cells including
monocytes and dendritic cells. The DC actively provides
surveillance for antigen and presents it to T cells after
processing. As such, the infected DC may play an im-
portant role in BVDV dissemination in body. The in-
fected DC may have altered surface marker expression
that interferes with mounting an effective immune re-
sponse. In this study, Mo-DC were used as an in vitro
model of DC. The ability of BVDV to replicate and pro-
duce infectious virus in monocytes and Mo-DC was in-
vestigated along with the effect of BVDV infection on
MHCI, MHCII, or CD86 expression. Four strains of
BVDV were used in this study including the severe acute
ncp BVDV2a 1373 strain, the moderate acute ncp
BVDV2a 28508-5 strain, and a virus pair (cp BVDV1b
TGAC and ncp BVDV1b TGAN) recovered from an ani-
mal that died of mucosal disease.
Results
Characterization of Mo-DC
Freshly collected monocytes were positive for MHCI
(96.62 ± 0.50%), MHCII (80.58 ± 19.69%), and CD14
(16.54 ± 1.49%) (Figure 1). After 7 days of differentiation
from monocytes to Mo-DC, the Mo-DC were positive
for MHCI (98.58 ± 0.34%), MHCII (94.1 ± 2.81%), CD205
(55.97 ± 45.48%), and CD86 (77.83 ± 17.83%), and werenegative for CD21 (3.42 ± 0.19%) and CD14 (1.025 ± 0.45)
(Figure 2). During the 7 days of differentiation, the MHCI
expressing cells increased from 96.62 ± 0.50% to 98.58 ±
0.34% (i.e., about 2%) and MHCII expressing cells in-
creased from 80.58 ± 19.69% to 94.1 ± 2.81% (i.e., roughly
17%), while CD14 expressing cells were significantly (P <
0.05) reduced from 16.54 ± 1.49% to 1.025 ± 0.45 (i.e.,
about 94%). Morphologically, Mo-DC increased 4-5 times
in size and developed long dendrites (Figure 3).
BVDV do not affect the Mo-DC viability
To determine the effect of BVDV infection on Mo-DC
viability, Mo-DC were infected with cp BVDV1b TGAC,
ncp BVDV1b TGAN, ncp BVDV2b 1373, or ncp
BVDV2b 28508-5 strains of BVDV at a multiplicity of
infection (MOI) of 6. Infected and mock-infected control
Mo-DC were collected at 1, 6, 12, 24, 48, and 72 hour(s)
post-infection. The viability of Mo-DC was determined
via trypan blue exclusion assay, as described by Strober
[8]. Results revealed that Mo-DC viability was not al-
tered significantly (p > 0.05) during the course of infec-
tion, regardless of BVDV strain (Figure 4).
Mo-DC do not produce infectious BVDV
Following 7 days of culture to differentiate monocytes to
Mo-DC (fully differentiated Mo-DC) freshly collected
monocytes, and Mardin-Darby Bovine Kidney (MDBK;
positive control) cells were infected with one of the four
BVDV strains (i.e., ncp BVDV2a 1373, ncp BVDV2a
28508-5, ncp BVDV1b TGAN, or cp BVDV1b TGAC
strain at an MOI of 6). Production of BVDV was mea-
sured at 1, 6, 12, 24, 48, 72, and 96 hour(s) post-
infection. The virus titer in supernatant or cell lysates
was measured as described by Reed and Muench [9]. No
infectious BVDV was produced by Mo-DC, regardless of
strain used, while monocytes and MDBK cells supported
production of infectious BVDV. Specifically, the BVDV
titers in MDBK cells for ncp BVDV2a 1373 peaked at
6.2 ± 0.71 log10/ml at 72 hours post-infection (Figure 5A);
ncp BVDV2a 28508-5 titers peaked at 6.7 ± 0.0 log10/ml
at 96 hours post-infection (Figure 5B); cp BVDV1b
TGAC titers peaked at 6.2 ± 0.71 log10/ml at 72 hours
post infection (Figure 5C); and ncp BVDV1b TGAN ti-
ters peaked at 6.2 ± 0.71 log10/ml at 96 hours post in-
fection (Figure 5D). Furthermore, BVDV titers in freshly
collected monocytes peaked at 3.67 ± 0.71 log10/ml for
ncp BVDV2a 1373 at 48 hours post infection (Figure 5A);
ncp BVDV2a 28508-5 titers peaked at 2.7 ± 0.0 log10/ml
at 72 hours post-infection (Figure 5B); cp BVDV1b TGAC
titers peaked at 4.7 ± 0.00 log10/ml at 72 hours post
infection (Figure 5C); and ncp BVDV1b TGAN titers
peaked at 3.7 ± 0.001 log10/ml at 48 hours post-
infection (Figure 5D). The BVDV infected Mo-DC did
not produce infectious virus (i.e., titers of 0.0); however,
Figure 1 Phenotype of adherent bovine monocytes. The adherent monocytes were stained with MHCI, MHCII or CD14 primary antibodies
followed by FITC-labeled secondary antibody. The experiments were repeated three times and mean expressions were calculated. A) Mean of
secondary antibody control showing 2.03 ± 0.7% stained cells; B) Cells showing mean MHCI expression as 96.62 ± 0.5%; C) Cells showing mean
MHCII expression as 80.58 ± 19.7%; and D) Cells showing mean CD14 expression as16.54 ± 1.5%.
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bovine herpesvirus 1 (BHV-1), indicating that the failure
of Mo-DC to produce virus was BVDV specific. The
BHV-1 titer peak was 4.7 ± 0.0 log10/ml at 48 hours
post-infection (Figure 6).
Mo-DC lose the ability to produce infectious BVDV during
differentiation
Cells were collected during the intermediate stages of
differentiation from monocytes to Mo-DC (i.e., at 48, 72,
96, and 120 hours) and infected with ncp BVDV2a 1373
at an MOI of 6. The cells were then collected at 24 or
48 hours post-infection and analyzed for virus titer in
cell lysate, as described by Reed and Muench [9]. Results
indicated that the ability of Mo-DC to produce virus is
lost during differentiation, and production of infectious
virus was completely halted by 120 hours of differenti-
ation. At 48 hours of differentiation from monocyte to
Mo-DC, cells produced 3.69 ± 0.00 log10/ml and 2.69 ±
0.00 log10/ml infectious BVDV at 24 and 48 hours post-infection, respectively; whereas, at 72 hours of differenti-
ation, the intermediate monocyte to Mo-DC produced
2.19 ± 0.71 log10/ml and 1.68 ± 0.00 log10/ml BVDV at 24
and 48 hours post-infection, respectively. At 96 hours of
differentiation, BVDV titers from Mo-DC were compara-
tively less (i.e., 1.69 ± 0.00 log10/ml and 0.85 ± 1.20 log10/
ml at 24 and 48 hours post-infection, respectively), and no
virus was produced by Mo-DC at 120 hours of differen-
tiation at 24 and 48 hours post-infection (Figure 7).
BVDV replicates viral RNA in Mo-DC
Mo-DC were not able to produce infectious BVDV;
therefore, the ability of Mo-DC to produce BVDV RNA
was examined. Viral RNA was extracted from BVDV-
infected Mo-DC at 0, 1, 6, 12, 24, 48, 72, 96, 144, 168,
and 192 hours post-infection. Viral RNA was quantified
at each time point using quantitative real-time polymer-
ase chain reaction (qRT-PCR) [10]. Testing indicated
that viral RNA replicated in Mo-DC. Interestingly, the
kinetics of viral RNA production differed between viral
Figure 2 Phenotype of Bovine Monocyte-Derived Dendritic Cell (Mo-DC). The Mo-DC at seven days of differentiation were stained for CD14,
CD21, CD205, MHCI, MHCII or CD86. The experiments were repeated three times and mean expressions were calculated. A) Cells showing mean
CD14 expression as 1.025 ± 0.45%; B) Cells showing mean CD21 expression as 3.42 ± 0.19%; C) Cells showing mean CD205 expression as 55.97 ± 45.48%;
D) Cells showing mean MHCI expression as 98.58 ± 0.34%; E) Cells showing mean MHCII expression as 94.1 ± 2.81%; and F) Cells showing mean CD86
expression as 77.83 ± 17.83%.
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BVDV2a 1373 strain began, peaked, and started to decline
at 24, 144, and 192 hours post-infection, respectively
(Figure 8A); replication of cp BVDV2a 28508-5 viral
RNA began at 6 hours, began to decline at 96 hours,
and was no longer producing viral RNA at 144 hours
post-infection (Figure 8B); replication of the cp BVDV1b
TGAC viral RNA began, peaked, and started to decline
at 1, 144, and 168 hour(s) post-infection, respectively
(Figure 8C); and production of the ncp BVDV1b TGAN
viral RNA began replicating at 12 hours, peaked at 72 hours,
and began to decline at 144 hours post-infection.
Comparisons were made between replication of BVDV
RNA in monocytes and Mo-DC. Freshly collected mono-
cytes were infected with ncp BVDV2a 1373 at an MOI of
6. The viral RNA was extracted from infected monocytes
at 0, 1, 6, 12, 24, 48, 72, 96, 144, 168, and 192 hour(s)
post-infection and was quantified at each time point using
qRT-PCR. Results showed that BVDV viral RNA started
to replicate in monocytes as early as 1 hour post-infection
and had ceased at 168 hours post-infection; whereas repli-
cation of viral RNA in Mo-DC began at a later time point
and had a longer duration (i.e., 24 through 168 hours
post-infection) (Figure 9).Mo-DC produced the BVDV non-structural (NS5A) and
envelope (E2) viral proteins
Viral RNA replicated in Mo-DC, but infectious virus was
not produced; therefore, to determine whether or not the
RNA was translated into viral proteins, a Western Blot
was performed. The test was completed using lysate har-
vested at 72 hours from Mo-DC or MDBK cells infected
with ncp BVDV2a 1373 at an MOI of 6. The ncp BVDV2a
1373 infected MDBK cells were used as positive control
while mock infected Mo-DC or MDBK cells were used as
negative control. The results showed that Mo-DC lysate
contained NS5A (Figure 10A) or E2 (Figure 10B), indicat-
ing that the infected Mo-DC produced viral proteins but
did not release infectious virus.
The cp biotype up-regulated and ncp biotypes down-
regulated MHCI, MHCII, and CD86 expression on Mo-DC
Following infection or mock-infection (i.e., control cells)
with the four strains of BVDV, the Mo-DC were stained
for MHCI, MHCII, or CD86 and fixed at 0, 1, 6, 12, 24,
48, and 72 hour(s) to determine the effects of infection
on cell surface expression. The mean fluorescent inten-
sity (MFI) in mock-infected Mo-DC at 0 hours was uti-
lized as 100%, the mock-infected Mo-DC at each time
Figure 3 Morphology of bovine monocyte derived dendritic cell. A) The Mo-DC at seven days of differentiation with bovine recombinant
IL-4 and GMCSF; B) Freshly collected monocytes.
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each time was calculated.
It was determined that MHCI expression in Mo-DC in-
fected with cp BVDV1b TGAC increased with the course
of infection. The expression of MHCI was up-regulated
from 100% at 0 hour to 133.50 ± 11.88% (i.e., appro-
ximately 33%), 189.10 ± 34.3% (i.e., roughly 89%), 230.2 ±Figure 4 Mo-DC viability after BVDV infection. Mo-DC were infected w
BVDV2a 1373 with a 6 MOI. The viability of Mo-DC was measured by trypan
and mean percentages of viable cells were calculated from 1, 6, 12, 24, 48,5.22%, (i.e., about 130%), 112.22 ± 17.29% (i.e., approxi-
mately 12%), 144.60 ± 53.14% (i.e., about 44%), and
158.16 ± 52.43% (i.e., roughly 58%) at 1, 6, 12, 24, 48,
and 72 hours post-infection, respectively, as compared
to time point controls (i.e., mock-infected Mo-DC). The
MHCI up regulation at 1, 6, 12, 24 or 48 hours post-
infection was significantly different then mock-infectedith cp BVDV1b TGAC, ncp BVDV1b TGAN, ncp BVDV2a 28508-5, or ncp
blue exclusion assay. The each experiment was repeated three times
and 72 hour(s) post-infection.
Figure 5 Virus production by Mo-DC, monocytes, and MDBK cells. The Mo-DC, monocytes, or MDBK cells were infected with ncp BVDV2a 1373 (A),
ncp BVDV2a 28508-5 (B), cp BVDV1b TGAC (C), or ncp BVDV1b TGAN (D) at an MOI of 6. Cells and supernatants were collected at 1, 6, 12, 24, 48, 72, and
96 hour(s) post-infection and analyzed for viral titer. Each experiment was repeated three times and mean virus titer was calculated at each time point.
Figure 6 BHV1 production by Mo-DC. The Mo-DC or MDBK cells were infected with the Cooper strain of BHV1 at an MOI of 6. Cells and supernatants
were collected at 1, 6, 12, 24, 48, 72, and 96 hour(s) post-infection and analyzed for viral titer. The experiment was repeated three times and mean virus titer
was calculated for both cells at each time point.
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Figure 7 Virus production of ncp BVDV2a-1373 strain of BVDV
by intermediate stages of cells differentiating from monocyte
to Mo-DC. Cells in the intermediate stages of differentiation were
harvested at 48, 72, 96, and 120 hours. Cells at each intermediate
stage of differentiation were infected with ncp BVDV2a 1373 strain
of BVDV with a 6 MOI. The cells were collected at 24 and 48 hours
post-infection and analyzed for viral titer. The experiment was
repeated three times and mean virus titer at each time point.
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pression was down-regulated following infection with
ncp BVDV strains as compared to mock-infected con-
trols. The expression of MHCI was down-regulated
from 100% at 0 hour to 64.15 ± 9.25% (i.e., about 36%),
41.30 ± 5.95% (i.e., about 59%) and 40.10 ± 7.18% (i.e.,
approximately 60%) at 72 hours post-infection following
ncp BVDV1b TGAN, ncp BVDV2a 28508-5 or ncp
BVDV2a 1373 infection respectively (Figure 11A). The
ncp BVDV1b TGAN infection to Mo-DC significantly
down-regulated the MHCI expression on Mo-DC at 1,
6, and 12 and 24 hour(s) post-infection as compared to
mock-infected control (P > 0.05). The ncp BVDV1a
28508-5 significantly (P < 0.05) down-regulated the
MHCI expression on Mo-DC at 24 and 72 hr post infec-
tion while the ncp BVDV1a 1373 infection down-
regulated MHCI expression at 24 and 48 hours post-
infection (P < 0.05) (Figure 11A).
Expression of MHCII increased during the course of
infection in Mo-DC infected with cp BVDV1b TGAC.
MHCII expression increased in cp BVDV1b TGAC in-
fected Mo-DC from 100% at 0 hour to 156.83 ± 54.48%
(i.e., roughly 56%) at 72 hours post-infection The MHCII
expression on Mo-DC following 6 hours infection with
cp BVDV1b TGAC was significantly higher than its time
point mock-infected control (P > 0.05) (Figure11B).
In contrast, MHCII expression was down-regulated in
Mo-DC, infected with ncp BVDV strains. The ncp
BVDV1b TGAN infection reduced the MHCII expres-
sion from 100% at 0 hour to 79.33 ± 19.33% (around
21%) at 72 hours post-infection. Similarly, expression of
MHCII was reduced from 100% at 0 hour to 56.44 ±13.01% (i.e., about 44%) and 55.10 ± 8.39% (i.e., approxi-
mately 45%) at 72 hours post infection following ncp
BVDV2a 28508-5 or ncp BVDV2a 1373 infection re-
spectively. The MHCII expression on Mo-DC was sig-
nificantly down-regulated at 6 and 12 hours post-
infection with ncp BVDV1b TGAN while ncp BVDV2a
28508-5 or ncp BVDV2a 1373 infection significantly
down-regulated the MHCII expression on Mo-DC at 12
and 72 hours post-infection as compare to their time
point control Mo-DC (P > 0.05) (Figure 11B).
Patterns of expression of CD86 in Mo-DC were similar
to those of MHCI and MHCII in regards to the BVDV
biotypes examined, as the cp biotype up-regulated and
the ncp biotypes down-regulated CD86 expression. Ex-
pression of CD86 in cp BVDV1b TGAC infected Mo-
DC was up-regulated from mock-infected controls as
100% at 0 hour to 261.22 ± 162.00 (i.e.160%) at 72 hours
post-infection (Figure 11C). Conversely, expression of
CD86 was decreased in Mo-DC infected with ncp
BVDV1b TGAN, ncp BVDV2a 28508-5 or ncp BVDV2a
1373 from 100% at 0 hour to 72.64 ± 1.38% (i.e. 28%),
76.31 ± 11.03% (i.e., about 24%) or 71.36 ± 4.08% (i.e.,
roughly 29%) at 72 hours post-infection, respectively.
The down-regulation of CD86 in ncp BVDV1b-TGAN,
ncp BVDV2a 28508-5 or ncp BVDV2a 1373 infected
Mo-DC was significant at 48 hours post-infection as
compare to their time point control (Figure 11C).
Discussion
This study revealed that Mo-DC and its progenitor cells
(i.e., monocytes) could become infected with the BVDV
virus; and while monocytes subsequently produced in-
fectious virus, Mo-DC did not. Furthermore, virus pro-
duction decreased with monocyte differentiation to Mo-
DC and had completely ceased by120 hours of differen-
tiation; thus, monocytes lost the ability to produce infec-
tious virus with differentiation to Mo-DC. It was also
determined that Mo-DC supported BVDV viral RNA rep-
lication but; the kinetics of viral RNA production was dif-
ferent between different viral strains. Additionally, viral
proteins were translated in BVDV infected Mo-DC; thus,
the accumulation of BVDV viral RNA and its subsequent
translation into viral proteins suggest that failure to pro-
duce infectious virus may be the result of a hindrance in
viral assembly, packaging, or release in Mo-DC. Further
studies using electron microscopy may confirm the actual
level of hindrance in infectious virus production.
A previous study that utilized a homologous pair of
BVDV ncp and cp viruses (i.e., Pe515ncp and Pe515cp)
revealed that Mo-DC were able to replicate and produce
infectious BVDV [11]. The difference in the ability of the
Mo-DC to produce infectious virus between that study
and the present study may be due to the use of different
monocyte isolation and Mo-DC culturing methods, as
Figure 8 Replication of BVDV viral RNA in Mo-DC or MDBK cells. Mo-DC or MDBK cells were infected with A) ncp BVDV2a 1373, B) ncp
BVDV2a 28508-5, C) cp BVDV1b-TGAC, or D) ncp BVDV1b TGAN strains of BVDV at an MOI of 6. Cells were collected at 0, 1, 6, 12, 24, 48, 72, 96,
144, 168 and 192 hour(s) post-infection. Viral RNA was extracted from the cells at each time point and quantified using qRT-PCR at each time
point. The experiments were repeated three times and mean value was calculated at each time point.
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current study examined Mo-DC that were determined
to be non-adherent CD14− cells. CD14 is a cell surface
marker specifically for monocytes and macrophages. It
acts as a co-receptor for bacterial lipopolysaccharide
(LPS) with toll-like receptor- 4 (TLR 4) [12]. CD14 ex-
pression is reduced during differentiation of monocytes
to Mo-DC [13,14]. Likewise, in another study, bovine
CD11b+Mo-DC also produced infectious BVDV; how-
ever, that study did not describe the culturing method,
phenotype, or morphology of the Mo-DC used [15].
CD11b is an adhesion molecule and complement recep-
tor that is expressed on neutrophils, monocytes, macro-
phages and Mo-DCs [16,17]. The above cell surface
molecules in combination with DEC205 are routinely
used to characterize the Mo-DC. DEC205 is a specific
marker of Mo-DC [18].
A number of studies have been performed using Mo-
DC and hepatitis C virus (HCV; another member of the
Flaviviridae family). Similarly, both BVDV and HCVhave a similar structural organization, can cause chronic
infections in their respective hosts, utilize the low-
density lipoprotein (LDL) receptor to enter the host
cells, and use a functionally similar internal ribosome
entry site (IRES) for translation. In addition, both viruses
use NS5B RNA-dependent RNA polymerase and have a
similar mechanism for virion maturation, assembly, and
release [19]. In one study, the J6/JFH strain (a chimeric
HCV of genotype 2a) did not replicate in B or T lym-
phocytes, monocytes, macrophages, or dendritic cells,
while it did replicate and produce infectious virus in
Huh-7.5 cells [20]; whereas, another study found that
Mo-DC infected with the JFH1 strain of HCV with an
MOI of 1did not support HCV RNA replication or anti-
gen production [21]. In contrast to the present study,
the mechanism responsible for the inability to produce
infectious HCV was different, as BVDV viral RNA was
replicated and translated into viral protein. This vari-
ation in HCV and BVDV replication may be due to their
replication requirements, as HCV tropism is restricted
Figure 9 Replication of ncp BVDV2a-1373 viral RNA in Monocytes, Mo-DC, or MDBK cells. Monocytes, MDBK cells, or Mo-DC were infected
with ncp BVDV2a-1373 at 6 MOI. Cells were collected at 0, 1, 6, 12, 24, 48, 72, 96, 144, 168 and 192 hour(s) post-infection. Viral RNA was extracted from
cells at each time point and quantified using qRT-PCR. The experiments were repeated three times and mean value was calculated at each time point.
Figure 10 Presence of NS5Aor E2 viral protein of BVDV in BVDV Infected Mo-DC. Mo-DC (lane 1 and 6) or MDBK cells (lane 2 and 5) were
infected with ncpBVDV1a-1373 with MOI of 6. The mock-infected Mo-DC (lane 3 and 8) or MDBK cells (lane 4 and 7) were used as negative
control. Cells were collected 72 hours post-infection. The Western Blot was performed using harvested cell lysate for BVDV NS5A or E2 viral
proteins. Specific NS5A protein (panel A) with band size of 56 kD or E2 protein (panel B) with band size of 53 kD in MoDC or MDBK cell lysate,
infected with ncp BVDV2a-1373 were observed.
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Figure 11 Effect of BVDV on Mo-DC cell surface marker expression. Differentiated Mo-DC were infected with either of four strains of BVDV,
including ncp BVDV2a 1373, ncp BVDV2a 28508-5, or a homologous pair of ncp or cp BVDV1b viruses (ncp BVDV1b TGAN or cp BVDV1b TGAC)
with an 6 MOI. The cells were stained for A) anti-MHCI; B) anti-MHCII or C) anti-CD86 antibody at 1, 6, 12, 24, 48, and 72 hour(s) post-infection.
The mock-infected Mo-DC) at each time point was used as control (white legend). The mean fluorescent intensity (MFI) of expression was
analyzed using flow cytometry. The each experiment was repeated three times. Asterisks (*) indicate significant difference from controls (P < 0.05).
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BVDV can replicate in epithelial and non-epithelial
cells [23].
A trial utilizing influenza virus in mouse bone marrow-
derived DC resulted in abortive replication. However,
viral genome transcription and replication occurred for
each gene segment along with the translation of viral
hemagglutinin and nucleoprotein. Further the study
using electron microscopy examination revealed that
the resulting failure was associated with defective viral
release, possibly due to insufficient synthesis or stability
of one or more viral proteins required for release of the
virus [24]. Similarly, the current study showed the
abortive replication of BVDV in Mo-DC. The exact
mechanism of abortive BVDV replication in Mo-DC is
not known. However future ultrastructural examination
of BVDV infected Mo-DC using electron microscopy
could be intriguing to understand the stage at which
production of infectious virus is blocked (i.e. assembly,
egress etc).
The current study showed that Mo-DC precursor mono-
cytes produced infectious BVDV while Mo-DC failed to
do so. It would be interesting to know the dynamics of
Mo-DC differentiation/maturation and viral production.
Previous studies have demonstrated that Mo-DC diffe-
rentiated with GMCSF and IL-4 were immature and could
be matured by proinflammatory cytokines, CD40L, IFN-γ
or LPS [13,25]. There has been little work done on effect
of BVDV strains on Mo-DC maturation. While it is well
established that cp BVDV induced more IFN-γ than ncp
BVDV in vitro [26,27], it is likely that cp BVDV strains in-
duce Mo-DC maturation more than ncp BVDV strains
in vitro. To confirm this hypothesis, a future study would
be helpful using different BVDV strains along with lipo-
polysaccharide (LPS) as maturation differentiation control.
One of the factors that may affect the production of
virus in Mo-DC is interaction with other cell popula-
tions. In this in vitro study, isolated cell populations
were used; whereas, testing in the in vivo environment
may result in different outcomes. Interaction of Mo-DC
with T cells in vivo may trigger the production of infec-
tious virus. In one study, the interaction of antigen pre-
senting cells (APC) with T cells enhanced HCV infection,
as the interaction of APC with T cells led to activation of
T cells [27]. Activated T cells produce interleukin-2 (IL-2),
a substance that enhances CD81 expression in thymocytes
[28]. Expression of CD81 on thymocytes facilitates theentry of HCV into cells, and thus, its replication [29].
Similarly, co-stimulation through interaction of CD28
and B7 increased HIV type 1 replication [30]. Therefore,
it stands to reason that other cell populations could be
affected. For example, the macrophage may become in-
fected by phagocytizing the apoptotic Mo-DC contai-
ning viral RNA and may then begin producing infectious
BVDV. As these probabilities are theoretical, exploration
using T cell activation assay or in vivo trials would be
beneficial.
The cell susceptibility can greatly be influenced with
changes in its surface receptor expression, particularly
receptors that mediate virus entry. BVDV infects cells
via Receptor-mediated endocytosis using the LDL recep-
tor [19]. Given that oxidized LDL has been demon-
strated to promote differentiation of dendritic cells from
monocytes in other species [31], it would be interesting
to explore the dynamics of LDL receptor expression dur-
ing monocyte to Mo-DC differentiation with respect to
cell infectivity and virus production. These future studies
could also explore the effect of different BVDV on LDL
expression for better understanding of the BVDV
pathogenesis.
In the current study, infection with BVDV affected cell
surface marker expression on Mo-DC. The cp BVDV1b-
TGAC strain enhanced MHCI, MHCII, and CD86 ex-
pression, while ncp strains of BVDV (i.e., ncp BVDV2a
1373, ncp BVDV2a 28508-5, and ncp BVDV1b TGAN)
reduced the MHCI, MHCII, and CD86 expression dur-
ing the course of infection. In another study that used
bovine monocyte-derived macrophages (MDM), MHCI
was up-regulated following infection with cp BVDV and
was down-regulated in cells infected with a ncp strain of
BVDV, while both cp and ncp strains down-regulated
the MHCII expression in MDM [32]. The difference in
MHCII results between that study and the present study
may be due to a difference in the cell types chosen for
analysis, as the Mo-DC reported here were non-adherent
CD14− cells, while the MDM were adherent CD14+ cells.
A study using differential detergent fractionation (DDF)
analysis of bovine monocytes showed that 53 bovine pro-
teins involved in the immune function of professional
APC were altered following BVDV infection. These al-
tered molecules include adhesion 151 molecules, toll-like
receptors (TLR 1, 6, and 8), antigen uptake, MHC I and II,
cytokines, and growth factor synthesis molecules [33]. The
above study supported the current finding that showed
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BVDV infected Mo-DC. The above study also showed the
alteration of cell adhesion molecules and capability of
antigen uptake by APC, that may affect the Mo-DC infect-
ivity and ultimately virus producing capability that need to
be explored.
The changes noted in surface marker expression on
Mo-DC could be due to differences in interferon expres-
sion between cp and ncp biotypes of BVDV. Type 1 IFN
plays an important role in up-regulation of MHCI expres-
sion [34], thus, reduced type 1 IFN production in Mo-DC
infected with ncp BVDV may explain the down-regulation
of MHCI and MHCII. Similarly, up-regulation of MHCI
and MHCII in Mo-DC infected with cp BVDV may be
due to an increase in type 1 IFN [26,35]. It would be inter-
esting to validate the effect of Type 1 IFN on cell surface
marker expression by using poly I:C treated cells as con-
trol. The previous study showed that ncp BVDV inhibited
of IFN induction was a result of blocking the IRF-3 path-
way [27]. It may be possible that BVDV affects other path-
ways such as the melanoma differentiation-associated
gene 5 (MDA5) signaling pathway, which will need to be
explored for better understanding of BVDV pathogenesis.
Alternatively, infection may have a direct effect on MHC
folding and assembly, and consequently, expression. For
example, infection with HCV changed MHCI expression
in infected cultured cancerous cells lines (i.e., human
hepatoma and mouse lymphoma cells) via disruption in
MHCI protein folding and assembly [36-38]. This study
found that HCV replicons induced endoplasmic reticulum
(ER) stress that resulted from a decline in protein glycosyl-
ation. The decrease in protein glycosylation disrupted pro-
tein folding and prevented the assembly of MHCI
molecules. Reduced assembly of MHCI molecules ultim-
ately resulted in MHCI down-regulation. Similarly, Hu-
man Immunodeficiency Virus (HIV) was shown to reduce
MHCI and CD86 expression via the Nef protein in a hu-
man embryonic kidney cell line (293 T), the human
monocytic U937 cell line, as well as in mouse macro-
phages and dendritic cells. The Nef protein binds and en-
docytoses MHCI molecules by the ARF6 pathway, thus
resulting in reduced MHCI expression [39,40]. The mech-
anism by which BVDV infection alters cell surface marker
expression needs to be explored, as this information
would provide a better understanding of immunosuppres-
sion caused by BVDV.
Conclusions
Findings from the current study demonstrated that Mo-
DC failed to produce infectious BVDV. The ability to
produce infectious BVDV was reduced with differenti-
ation of monocyte to Mo-DC and completely stopped at
120 hours of differentiation. However, BVDV viral RNA
replicated and was translated into viral proteins in Mo-DC, indicating that inability to produce infectious virus
may be due to assembly or release of virus. Infection of
Mo-DC with the cp strain of BVDV up-regulated ex-
pression, while infection with ncp strains of BVDV
down-regulated expression of the cell surface markers
MHCI, MHCII, and CD86. The up-regulation of cell
surface marker expression that results from cp BVDV
infection may explain why a better immune response is
induced when modified live virus vaccines that contain
cp strains of BVDV are used. On the other hand, the
down-regulation of cell surface marker expression by
ncp strains of BVDV may be an important function of




Brown Swiss calves (8-12 months of age) were used in this
study. All animals were deemed healthy prior to use and
were housed at the Dairy Farm at South Dakota State
University, Brookings, SD, U.S.A. Animal handling and
blood collection were approved (approvals # 09-039E
and 12-052A) and performed according to the guidelines of
the SDSU Institutional Animal Care and Use Committee.
Isolation of monocyte and differentiation into Mo-DC
(Monocyte-derived dendritic cell)
Peripheral blood mononuclear cells (PBMC) were isolated
from the whole blood of healthy calves using gradient cen-
trifugation using 65% percoll (GE Healthcare Biosciences,
Pittsburgh, PA, USA. PBMC were cultured at 37°C in 6-
well plates using Roswell Park Memorial Institute medium
(RPMI) 1640 medium supplemented with 10% fetal bovine
serum (FBS), penicillin (100 U/ml) and streptomycin
(100 μg/ml) for three hours. The adherent cells were
harvested using Accutase (eBioscience, San Diego, CA,
USA) and confirmed as MHCI+, MHCII+, and CD14+
monocytes. The monocytes were cultured in RPMI 1640
medium supplemented with 20% FBS, 1 mM sodium
pyruvate, penicillin (100 U/ml), streptomycin (100 μg/
ml), recombinant bovine GM-CSF (100 ng/ml) and IL-4
(200 ng/ml) for 7 days. A 750 μl medium supplemented
with cytokine was added to each well on alternate days,
and the loosely attached or floating Mo-DC were har-
vested on day 7 and were confirmed morphologically
and phenotypically. Morphologically, Mo-DC were 4 to
5 times larger than monocytes and had long dendrites.
Phenotypically, Mo-DC were determined as MHCI+,
MHCII+, CD86+, CD205+, CD14−, and CD21−.
Virus
The Cooper strain of bovine herpesvirus1 (BHV1) and four
strains of BVDV [i.e., a homologous pair of ncp and cp vi-
ruses (ncp BVDV1b TGAN and cpBVDV1b TGAC)
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severe acute ncp BVDV2a 1373); and the moderate acute
ncp BVDV2a 28508-5 strain] were used in this study. All
the BVDV virus stock used in the study was kindly
provided by Dr. Julia F Ridpath (Ruminant Diseases and
Immunology Research Unit, National Animal Disease
Center, USDA, Ames, IA, USA).
Cells
Passage 95–110 of BVDV free MDBK cells, grown in
minimal essential medium (MEM, Gibco BRL, Grand
Island, NY) at a pH of 7-7.4, and supplemented with 10%
BVDV free fetal calf serum (PPA, Pasching, Austria), peni-
cillin (100 U/ml), and streptomycin (100 μg/ml) were used
in the study.
Virus titration
Freshly collected monocytes, fully differentiated Mo-DC,
and MDBK cells were infected with ncp BVDV2a 1373,
ncp BVDV2a 28508-5, cp BVDV1b TGAC, or ncp
BVDV1b TGAN at an MOI of 6. The cell lysate or
supernatant were collected at 0, 1, 6, 12, 24, 48, 72, and
96 hour(s) post-infection. Virus titers in cell lysate or
supernatant at each time point were determined as de-
scribed by Reed and Muench [9]. Additionally, cells
were infected with BHV1 at the same MOI and were
used as positive control for virus replication at the
same time points.
To determine at which time point of differentiation Mo-
DC lose infectious virus production capacity, the mono-
cytes, cells of intermediate stages at 48, 72, 96 and 120 hours
of differentiation were infected with ncp BVDV2a 1373 at
an MOI of 6. The cells were collected at 24 and 48 hours
post-infection and analyzed for virus titer in cell lysate.
Viral RNA isolation and quantification
Fully differentiated Mo-DC and MDBK cells were infected
with ncp BVDV2a 1373, ncp BVDV2a 28508-5, cp
BVDV1b TGAC, or ncp BVDV1b TGAN at an MOI of 6.
Cells were collected at 1, 6, 12, 24, 72, 96, 120, 144, 168,
and 192 hour(s) post-infection. Viral RNA was isolated
from infected cells using the QIAamp Viral RNA Mini kit
(Qiagen, Valencia, CA, USA) and was quantified by qRT-
PCR (Stratagene MX3000P Real-Time Thermocycler,
Stratagene Inc., La Jolla, USA) in 25 μl reaction with 6-
carboxy-fluorescein (FAM) dye. The qRT-PCR targeted
the 5′ untranslated region (5′UTR) of viral genome using
the following primers: forward = 5-GGGNAGTCGTCA
RTGGTTCG-3; and reverse = 5-TGCCATGTACAGCA-
GAGWTTTT-3) [10].
To compare the viral replication dynamics in mono-
cytes, fully differentiated Mo-DC and MDBK cells, the
cells were infected with ncp BVDV2a1373. Viral RNA
was isolated and quantified using qRT-PCR, as describedabove. The RNA extracted from non-infected cells was
used as internal control at each reaction.
Western blot
To determine whether BVDV viral RNA was translated
into viral proteins in Mo-DC, a Western blot was per-
formed targeting one structural protein (envelope pro-
tein -2: E2) that play a major role in virus attachment
and entry to host cell [41] and non-structural protein 5A
(NS5A), that interacts with the host cellular protein and
inhibits NF-B activation [42]. Western blot was per-
formed as described by Devireddy and Jones [43], with
some modifications. The MDBK cells or Mo-DC were
infected with ncp BVDV2a 1373 at an MOI of 6for
72 hours, washed with PBS, and then lysed with 200 μl
of RIPA buffer containing the complete ULTRA tablet
containing protease inhibitor (Roch Diagnostic, GmbH,
Sandhofen, Germany). The mock infected MDBK cells
or Mo-DC were used as control. The cell lysate was cen-
trifuged at 13,000 rpm for 5 minutes and the super-
natant was collected. Forty μl of cell lysate was loaded in
12.5% sodium dodecyl sulfate -polyacrylamide gel elec-
trophoresis (SDS-PAGE) and the dual color protein lad-
der (10-250kD; Bio-Rad, Hercules, CA, USA) was used
as a standard. The proteins were transferred onto a
nitrocellulose membrane (Whatman GmbH, Dassel,
Germany), blocked with5% skim milk in PBS for 30 mi-
nutes at room temperature, and then incubated at 4°C
overnight with either anti-BVDV NS5A rabbit polyclonal
antibody (produced in our laboratory using a recombin-
ant BVDV NS5A as an immunogen) or anti-BVDV E2
mouse monoclonal antibody (15-C5, IDEXX Laboratories,
Inc., Westbrook, Maine, USA) at a dilution of 1:1000 in
PBS containing 1% skim milk. Following three washes
with PBS containing 0.5% Tween 20, the membrane was
incubated overnight at 4°C with for BVDV E2 or BVDV
NS5A with diluted (1:3000) PBS containing 1% skim milk
and either goat anti-mouse (IRDye 800CW, LI-COR
Biosciences, Lincoln, NE, USA) or goat anti-rabbit (IRDye
800CW, LI-COR Biosciences, Lincoln, NE, USA), respect-
ively. The specific protein band was visualized by using
the Odyssey Imaging system and software (LI-COR Bio-
sciences, Lincoln, NE, USA).
Flow cytometry analysis
Flow cytometric analysis was performed to phenotypically
characterize the harvested monocytes and Mo-DC, and to
determine the effect of BVDV infection on Mo-DC cell
surface marker expression. For monocyte characterization,
three monoclonal antibodies (mAb) against MHCI
(H58A), MHCII (H42A), and CD14 (MM61A) were
used; while Mo-DC were characterized using six primary
mouse mAb antibodies against bovine MHCI (H58A),
MHCII (H42A), CD86 (IL-A190A), CD21 (BAQ15A), and
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USA), as well as CD205 (provided by Dr. Waithaka
Mwangi, Texas A&M University, USA). To block the non-
specific binding, primary and secondary antibodies were
diluted in 1% FBS in PBS. The primary antibodies were
used as 1:100 dilution in 1% FBS in PBS while fluorescein
isothiocyanate (FITC) labeled anti-mouse antibody
(VMRD Inc., Pullman, WA, USA) was used as 1:1000 di-
lution in 1% FBS in PBS as secondary antibody. Mock-
infected or BVDV- infected cells were collected at 0,
1,6,12, 24, 48 or 72 hour (s) post-infection. Collected cells
were centrifuged at 200 g for 10 minutes at 4°C. Cell pel-
lets were washed with 1%FBS in PBS. The cell staining
was performed in round bottom 96 well plates. The col-
lected cells were suspended in 50 μl primary antibody and
incubated for 10 minutes at 4°C. The cells were washed
two times with 1%FBS in PBS and suspended in 50 μl
FITC labeled anti-mouse antibody. The cells were incu-
bated in secondary antibodies for 10 minutes at 4°C and
washed two times with 1% FBS in PBS. Following staining,
the cells were suspended in 200 μl of 1% paraformalde-
hyde for fixing and analyzed using a dual-laser FACSCali-
bur (Becton-Dickson, Mountain View, CA, USA). To
confirm nonspecific binding/ Fc receptor blockage, the
cells were stained with FITC labeled anti-mouse antibody
(secondary antibody) at each time points. Nonspecific
binding of all primary antibodies was negligible based on
these analyses. Each experiments was repeated a mini-
mum of 3 times and significant different was determined
by paired T test at 5% level of significance [44].
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